- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01646580
Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children
July 19, 2012 updated by: Ferrer Internacional S.A.
Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses
Ciclopirox olamine (Ciclochem®) is a pyridone broad spectrum antifungal drug which has shown activity on dermatophytes, yeasts, moulds, actinomycetes and some bacteria.
Its mechanism of action is based on a fungicidal activity by inhibiting the cellular captation of essential substances needed for the metabolism and growth of the fungi.
On the other hand, this drug binds irreversibly with cell structures as mitochondria, ribosomes, microsomes and cell wall.
After dermal application, Ciclopirox olamine undergoes skin penetration, being only absorbed a 1,5% of the applied dose.
Clinical efficacy has been studied in patients above 10 years with superficial dermatomycoses (dermatophytoses, candidiasis and pityriasis versicolor) and the percentage of clinical healing ranged from 77% to 91% after 2-4 weeks of twice a day topical application.
In all the studies, the safety profile has been very good, showing only a very low rate of adverse events of mild to moderate intensity.
There are very few previous available data on the application of this compound in children under 10 years of age.
A single study had been performed with a solution formulation in patients from 6 to 29 months with diaper candidiasis, showing good efficacy and tolerability in these patients.
The present study aims to show the safety and tolerability of ciclopirox olamine in a cream formulation in patients from 3 months to 10 years with dermatomycoses.
Study Overview
Detailed Description
A multicenter, open, prospective, Phase IV study of Ciclopirox olamine on patients from 3 months to 10 years with all kinds of dermatomycoses.
All body areas were treatable except scalp and nails (no tinea on the scalp nor onychomycoses) .
Cream applied BID between 6.00 and 10.00am and 7.00 and 10.00pm daily for 4 weeks.Control visit after 4 more weeks without treatment was performed in order to evaluate the relapse rate.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 8 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients from 3 months to 10 years of age.
- Patients diagnosed of dermatomycoses produced by yeasts or dermatophytes by KOH technique at the inclusion moment, which has to be confirmed by culture.
- Obtention of the informed consent of the parents or legal representatives of the patients
Exclusion Criteria:
- Previous treatment with oral or topical antifungal drugs.
- Hypersensitivity to ciclopirox olamine or some of the cream excipients.
- Use of topical or oral steroids concomitantly.
- Patients with mycoses on the scalp or nails.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ciclopirox
|
Doses of 1.0% cream.
Topical cream application.
Twice daily for 28 days.
Duration of treatment: 28 days with four weeks follow-up.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate skin lesion condition as a measure of safety and tolerability of ciclopirox olamine treated dermatomycoses patients from 3 months to 10 years.
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Explore clinical efficacy of topically applied ciclopirox olamine cream in patients with dermatomycoses.
Time Frame: 0, 7, 14, 21 and 28 days
|
0, 7, 14, 21 and 28 days
|
Explore mycological efficacy of topically applied ciclopirox olamine cream in patients with dermatomycoses
Time Frame: 0, 7, 14, and 28 days
|
0, 7, 14, and 28 days
|
Explore relapse rate
Time Frame: day 56
|
day 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jose C Moreno, Prof, PhD, Hospital Reina Sofia, Cordoba, Spain
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
July 12, 2012
First Submitted That Met QC Criteria
July 19, 2012
First Posted (Estimate)
July 20, 2012
Study Record Updates
Last Update Posted (Estimate)
July 20, 2012
Last Update Submitted That Met QC Criteria
July 19, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPO_08_01
- 2008-003560-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatomycoses
-
Central Hospital, Nancy, FranceRecruiting
-
Sara BotrosCompleted
-
Boni Elewski, MDCompleted
-
National Institute of Allergy and Infectious Diseases...University of Alabama at BirminghamCompleted
-
Sara BotrosCompleted
-
The University of The West IndiesNot yet recruitingTinea VersicolorJamaica
-
Philippine Dermatological SocietyCompletedTinea Imbricata
-
Merz North America, Inc.CompletedTinea CorporisUnited States, Dominican Republic, Honduras
-
Universidad Complutense de MadridNot yet recruiting
Clinical Trials on ciclopirox
-
University Health Network, TorontoThe Leukemia and Lymphoma SocietyCompletedAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myelodysplasia | Hodgkin's DiseaseCanada
-
Galderma R&DCompleted
-
Atlas Molecular PharmaCompletedAdverse Effect of Drugs and Medicaments in Therapeutic UseUnited States
-
Moberg Pharma ABCompletedDistal Subungual OnychomycosisGermany, United Kingdom, Poland
-
MIP Brasil Indústria e Comércio de Produtos Farmacêuticos...Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda MEUnknown
-
University of Medicine and Dentistry of New JerseyWithdrawn
-
Rady Children's Hospital, San DiegoCompleted
-
University Hospital, RouenCompletedSevere Seborrheic DermatitisFrance